All In Biotech

Free tool

FAERS Monitor: Evotaz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206353 or its brand name (Evotaz, Atazanavir Sulfate, Cobicistat). Reports on generic versions are filed under their own applications.

Reports

245

Serious

184

75% of reports

Hospitalization

23

Death reported

16

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain43
  • emotional distress40
  • anxiety39
  • anhedonia36
  • osteoporosis25
  • chronic kidney disease21
  • foetal exposure during pregnancy21
  • bone density decreased18
  • osteopenia18
  • renal failure15
  • maternal exposure during pregnancy14
  • depression13
  • economic problem13
  • gait disturbance11
  • exposure during pregnancy10

Reports by year received

View as table
YearReports
201512
201621
201736
201824
201928
202034
202154
202212
202320
20241
20253

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,914 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anhedoniaSignal36117.887.14,051
osteopeniaSignal18102.065.31,699
economic problemSignal1373.743.4861
osteoporosisSignal2552.236.01,207
bone density decreasedSignal1849.331.6806
emotional distressSignal4028.421.41,035
chronic kidney diseaseSignal2123.715.8436
foetal exposure during pregnancySignal2122.214.7405
exposure during pregnancySignal1013.87.5107
maternal exposure during pregnancySignal1413.58.1150
anxietySignal3911.88.8379
renal failureSignal159.75.9109
painSignal436.04.6180
gait disturbanceSignal114.92.831
depressionSignal134.92.937

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.